All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
The present invention relates generally to implantable neural stimulators, and more specifically to a nerve cuff with a pocket for removably receiving an active leadless stimulation device, and methods of stimulating a nerve using such nerve cuff.
Implantable electrical stimulation devices have been developed for therapeutic treatment of a wide variety of diseases and disorders. For example, implantable cardioverter defibrillators (ICDs) have been used in the treatment of various cardiac conditions. Spinal cord stimulators (SCS), or dorsal column stimulators (DCS), have been used in the treatment of chronic pain disorders including failed back syndrome, complex regional pain syndrome, and peripheral neuropathy. Peripheral nerve stimulation (PNS) systems have been used in the treatment of chronic pain syndromes and other diseases and disorders. Functional electrical stimulation (FES) systems have been used to restore some functionality to otherwise paralyzed extremities in spinal cord injury patients.
Typical implantable electrical stimulation systems can include a system with one or more programmable electrodes on a lead that are connected to an implantable pulse generator (IPG) that contains a power source and stimulation circuitry. However, these systems can be difficult and/or time consuming to implant, as the electrodes and the IPG are usually implanted in separate areas and therefore the lead must be tunneled through body tissue to connect the IPG to the electrodes. Also, leads are susceptible to mechanical damage over time as they are typically thin and long.
Recently, small implantable neural stimulator technology, i.e. microstimulators, having integral electrodes attached to the body of a stimulator has been developed to address the disadvantages described above. This technology allows the typical IPG, lead and electrodes described above to be replaced with a single device. Elimination of the lead has several advantages including reduction of surgery time by eliminating, for example, the need for implanting the electrodes and IPG in separate places, the need for a device pocket, tunneling to the electrode site, and strain relief ties on the lead itself. Reliability is therefore increased significantly, especially in soft tissue and across joints because active components, such as lead wires, are now part of the rigid structure and are not subject to the mechanical damage due to repeated bending or flexing over time.
However, the leadless integral devices tend to be larger and more massive than the electrode/lead assemblies, making it difficult to stably position the device in the proper position in respect to a nerve. Without device stability, the nerve and/or surrounding muscle or tissue can be damaged due to movement of the assembly.
There remains a need for a leadless integral device that is stably positioned on the nerve, and can provide for removal and/or replacement of the stimulation device with relative ease.
Described herein are extravascular nerve cuffs for securing a leadless, integral, implantable device to a nerve. The nerve cuff typically includes a pouch or pocket. The cuff electrode configuration of the stimulation device allows the device to be stably positioned proximate a nerve, such as the vagus nerve. Furthermore, the cuff electrode configuration also has the characteristics of driving most of the current into the nerve, while shielding surrounding tissues from unwanted stimulation. Methods of securing a leadless microstimulator using such nerve cuffs are also described herein, as well as methods of stimulating a nerve using microstimulators secured using such cuffs.
There are numerous advantages to using leadless cuffs with a microstimulator, including a decrease in encapsulation (e.g., to about 100 microns) compared to systems without leadless cuffs, since there is less “tugging” on the leadless cuff. Furthermore, leadless cuffs, which may securely attach to a nerve and hold a microstimulator in position, may allow a microstimulator to be modified or replaced while maintaining the same positioning relative to the nerve.
In one embodiment of the invention, the nerve cuff generally includes a cuff body or carrier, made of a flexible material such as a medical-grade soft polymeric material (e.g., Silastic™ or Tecothane™) forming a cuff or sleeve, having a pocket or pouch defined therein for removably receiving a leadless stimulation device. The leadless stimulation device is positioned within the pocket or sleeve such that the electrodes of the device are positioned proximate the nerve to be stimulated. The pocket can be defined by the space between the stimulation device and an inner surface of the cuff body or can comprise a pouch-like structure attached to the cuff body for containing the stimulation device. The nerve cuff can be coupled to the nerve, a surrounding sheath that contains the nerve, or both depending on the desired level of stability.
The nerve cuff can be implanted by first dissecting the nerve, such as the vagus nerve, from its surrounding sheath, wrapping the nerve cuff around the nerve, coupling or suturing the nerve cuff to one of either the nerve or the sheath and inserting the stimulation device within the pocket or pouch of the cuff body such that the stimulation device is proximate the nerve.
For example, described herein are nerve cuffs for securing a leadless microstimulator in stable communication with a nerve. A nerve cuff may include: a cuff body having a channel extending within the length of the cuff body for passage of a nerve; a pocket within the cuff body, configured to removably hold the leadless microstimulator; and an elongate opening slit extending the length of the cuff body configured to be opened to provide access to the pocket.
The nerve cuff may also include an internal electrical contact within the cuff body. For example, the internal electrical contact may be configured to electrically couple the microstimulator and the nerve. In some variations, the nerve further includes an external electrical contact on the outer surface of the cuff body configured to couple with the microstimulator.
In some variations, the cuff body comprises shielding configured to electrically isolate the microstimulator within the nerve cuff. The cuff body may be of uniform thickness, or it may have a non-uniform thickness. For example, the cuff body may have a thickness between about 5 and about 20 mils.
In some variations, the outer surface of the nerve cuff is substantially smooth and atraumatic. The nerve outer surface of the nerve cuff may be rounded and/or conforming. For example, the body may conform to the region of the body into which the cuff and/or microstimulator are implanted.
In some variations, the channel comprises a support channel configured to support the nerve within therein, to prevent pinching of the nerve.
The elongate opening slit may extend the length of the cuff body in an interlocking pattern. In some variations, the slit extends along the side of the cuff body, adjacent to the channel. In other variations, the slit extends along the top of the cuff body, opposite to the channel.
The nerve cuff may also include one or more attachment sites in the elongate opening slit configured to help secure the slit closed. For example, the attachment sites may be holes or passages for a suture.
In some variations, the cuff body is formed of a flexible and biocompatible polymer (e.g., a polymeric biocompatible material such as a silicone polymer.
Also described herein are nerve cuffs for securing a leadless microstimulator in stable communication with a nerve, comprising: an insulating cuff body having a nerve channel extending within the length of the cuff body for passage of a nerve, wherein the cuff body electrically isolates the microstimulator within the cuff body; a conductive surface within the nerve channel configured to engage one or more electrical contacts on the microstimulator; a pocket within the cuff body, configured to removably hold the leadless microstimulator; and an elongate opening slit extending the length of the cuff body configured to be opened to provide access to the pocket.
As mentioned above, the nerve cuff may include one or more external electrical contact on the outer surface of the cuff body configured to couple with the microstimulator.
In some variations, the nerve cuff body has a uniform thickness; in other variations, the nerve cuff body has a non-uniform thickness. The cuff body may have a thickness between about 5 and about 20 mils.
The outer surface of the nerve cuff may be substantially smooth and atraumatic. For example, the outer surface of the nerve cuff may be contoured.
In some variations, channel through the nerve cuff comprises a support channel configured to support the nerve within therein, to prevent pinching of the nerve.
In some variations, the elongate opening slit extends the length of the cuff body in an interlocking pattern. For example, the interlocking pattern may be a zig-zag pattern, or a sinusoidal pattern.
Also described herein are methods of implanting a leadless microstimulator in communication with a vagus nerve, the method comprising: exposing a vagus nerve; opening a slit of a nerve cuff having a nerve cuff body, wherein the slit opens along the length of the nerve cuff body; placing the nerve cuff around the vagus nerve so that the nerve is within a channel extending the length of nerve cuff; inserting a leadless microstimulator within a pocket in the nerve cuff; and securing the slit of the nerve cuff closed so that the leadless microstimulator is in electrical communication with the nerve and electrically isolated within the nerve cuff body.
In some variations, the step of securing the opening slit of the nerve cuff closed comprises securing the slit so that the leadless microstimulator engages an internal electrical contact within the nerve cuff body. The leadless microstimulator may engage an internal electrical contact configured to provide circumferential stimulation around the nerve within the channel.
The step of securing may comprise suturing the slit closed. In some variations, the slit may be self-closing. For example, there may be enough tension in the cuff to keep it closed by itself. In some variations, dissolvable sutures may be used to keep it closed until the body encapsulates it.
The method may also include the step of testing the microstimulator to confirm electrical communication with the nerve.
In some variations, the step of placing the nerve cuff comprises placing an oversized nerve cuff around the vagus nerve.
Also described herein are methods of implanting a leadless microstimulator in communication with a vagus nerve including the steps of: exposing a vagus nerve; opening a slit of a nerve cuff having a nerve cuff body, wherein the slit opens along the length of the nerve cuff body; placing the nerve cuff around the vagus nerve so that the nerve is within a channel extending the length of nerve cuff; inserting a leadless microstimulator within a pocket in the nerve cuff so that the microstimulator communicates with one or more internal electrical contacts within the nerve cuff; and closing the slit of the nerve cuff so that the nerve is in electrical communication with the one or more internal electrical contact.
In some variations, the leadless microstimulator and the internal electrical contact is configured to provide circumferential stimulation around the nerve within the channel. The step of closing may include the step of securing the slit of the nerve cuff closed. For example, the step of closing may comprise suturing the slit closed. The step of placing the nerve cuff may comprise placing an oversized nerve cuff around the vagus nerve.
The above summary of the invention is not intended to describe each illustrated embodiment or every implementation of the present invention. The figures and the detailed description that follow more particularly exemplify these embodiments.
While the invention is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit the invention to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the appended claims.
Embodiments of the invention are directed to a retaining device, such as a carrier or cuff, which positions active contacts, i.e. electrodes, of a stimulation device against the targeted nerve directing the current from the electrodes into the nerve. The retaining device also inhibits or prevents the current from flowing out to the surrounding tissue.
Referring to
In general, a nerve cuff including a cuff 104 body having (or forming) a pouch or pocket 106 for removably receiving an active, implantable stimulation device 108 having one or more integrated, leadless electrodes 110 on a surface of stimulation device 108 proximate nerve 102. As illustrated in
Contacts or electrodes 110 can be positioned directly against nerve 102, as illustrated in
In one embodiment, the pocket 106 for containing the stimulation device 108 is defined by the open space between the nerve 102 and the inner surface of the cuff body 104. Stimulation device 108 can be passively retained within pocket 106 by the cuff body 104, or can be actively retained on cuff body with fastening means, such as, for example, sutures. In other embodiments, pocket 106 can comprise a pouch-like structure attached to cuff body 104 into which stimulation device 108 can be inserted. Stimulation device 108 can be passively retained within a pouch-like pocket by simply inserting the device 108 into the pocket or can be actively retained with fastening means. A pouch-like pocket can be positioned either in the interior or on the exterior of cuff body 104. Pouch-like pocket 106 and/or cuff body 104 can include access openings to allow electrodes to be positioned directly proximate or adjacent to nerve 102.
Cuff body 104 can have a constant thickness or a varying thickness as depicted in
A key obstacle to overcome with implanting stimulation devices proximate nerves or nerve bundles is attaching a rigid structure that makes up the stimulation device along a fragile nerve in soft tissue. In one embodiment of the invention, this issue is resolved by encasing nerve 102 and device 108 in a cuff body 104 that comprises a low durometer material (e.g., Silastic™ or Tecothane™) as described above, that conforms around nerve 102. Further, as illustrated in
Given the design or architecture of cuff body 104, any vertical movement of cuff body 104 on nerve 102 is not critical to electrical performance, but can result in friction between device 108 and nerve 102 that could potentially damage nerve 102. For that reason, device 108 should readily move up and down nerve 102 without significant friction while being sufficiently fixated to nerve 102 so that eventually connective tissue can form and aid in holding device 108 in place. The challenge is stabilizing device 108 so that it can be further biologically stabilized by connective tissue within several weeks.
Nerve cuff 100 should not be stabilized to surrounding muscle or fascia that will shift relative to the nerve. Therefore, referring to
Several stabilizing mechanisms can be used, including suture tabs and holes, staples, ties, surgical adhesives, bands, hook and loop fasteners, and any of a variety of coupling mechanisms.
Muscle movement against cuff adapter 100 can also transfer undesired stresses on nerve 102. Therefore, in an embodiment of the invention, low friction surfaces and/or hydrophilic coatings can be incorporated on one or more surfaces of cuff body 104 to provide further mechanisms reducing or preventing adjacent tissues from upsetting the stability of nerve cuff 100.
As discussed supra, compression of nerve 102 must be carefully controlled. Excess compression on nerve 102 can lead to devascularization and resulting death of the neural tissue. Compression can be controlled by over-sizing or rightsizing nerve cuff 100, so that when pocket sutures 124 are maximally tightened, the nerve diameter is not reduced less that the measured diameter. Cuffs formed from Silastic™ or Tecothane™ materials are relatively low cost, and therefore several sizes can be provided to the surgeon performing the implantation of nerve cuff 100 to better avoid nerve compression.
Miniature stimulators, such as device, are still large enough to be felt and palpated by patients as are state-of-the-art commercial cuff systems. Referring to
When a nerve does not provide sufficient structural strength to support nerve cuff adapter 100, collateral structures can be included in or on cuff body 104. Because of a high degree of anatomical variance such a scheme must demand the skill of the surgeon to utilize a highly customizable solution.
The exemplary cuff shown in
For Example,
Both nerve cuff variations shown in
As can be seen from
As mentioned briefly above, in some variations of the nerve cuff the inner surface of the cuff body includes one or more internal contacts configured to couple with the microstimulator held within the pouch, and transmit any applied energy to the nerve (or receive energy from the nerve) positioned within the channel through the nerve cuff. The internal lead may be positioned so that it applies current to the underside (along the bottom region of the channel), or around the sides of the nerve as it sits within the channel. In some variations the internal conductor or lead is configured around the channel so that the nerve may be circumferentially stimulated, optimizing the applied stimulation.
Many of the nerve cuff variations described herein may be opened and positioned around the nerve, for example, by splitting them open along a slit or hinge region. The device may be configured so that they have sufficient resiliency to close themselves, or remain closed if the edges of the slit region are brought together. Thus, the device may have a shape memory property that encourages them to close. In some variations, as already mentioned, it may be useful to hold them closed, at least temporarily, once they have been positioned over a nerve and the microstimulator has been positioned within the pocket. Thus, the device may include one or more closure elements. For example, the device may include a suture hole or passage for suturing the device closed. In some variations the nerve cuff includes a button or other fastener element. In some variations, as illustrated in
Any of the nerve cuffs described herein may also include one or more external leads or contacts facing the outside of the nerve cuff body, which may be used to stimulate tissues outside of the nerve cuff, and not just the nerve within the channel through the cuff.
A nerve may sit within a supported channel through the nerve cuff. As illustrated in
In general, the nerve cuff body may be electrically insulating, preventing leakage of charge from the microstimulator during operation. In some variations the nerve cuff includes shielding or insulation sufficient to electrically insulate the microstimulator within the nerve cuff body. Shielding material may particularly include electrically insulative materials, including polymeric insulators.
It may be shown mathematically using an equivalent circuit of the microstimulator, as shown in
For example, assuming a nerve with a cross section of Narea is surrounded by a column of fluid Farea enclosed by the nerve cuff, where contacts on the inside the microstimulator are spaced Espacing apart (center to center) and have a width Ewidth and circle around the column of fluid and nerve Ddegrees, it can be shown that the current will leak out the ends through a distance between the center of the electrode and the end of the nerve cuff that is defined by a distance Dguard.
The electrical model (illustrated in
If the nerve has a tight fit, then all the current passing through Rs would contribute towards stimulation, but only a portion of the current can activate the nerve in the case of a loose fit. Based on this model, it can be shown that (assuming that the nerve and fluid columns form an ellipse defined by the major and minor axis a and b, and the pulse width is short and capacitances are large) just the real impedance and efficiency can be estimated.
The electrode surface area is determined to estimate the complex portion of the impedance: Farea=π*aF*bF and Narea=π*aN*bN.
Assuming the impedance of the cuff contained fluid and nerve has a similar conductance p and electrodes are spaced at Espacing then the real resistance of the conduction volume is: Rworking=Espacing*ρ/Farea, where the wasted resistance that should be maximized is calculated by: Rwasted=2*Dguard*ρ/Farea+Rbulk, where Rbulk is defined as the free field resistance between the two ends of the cuff.
So the efficiency (η) of the real current delivered in the POD is Rwasted/(Rworking+Rwasted), and for the case of an undersized nerve assuming the conductivity of tissue and the fluid column is about equivalent then the stimulation efficiency is defined as ηT=η*Narea/Farea.
Methods of Insertion
In operation, any of the devices described herein may be positioned around the nerve, and the microstimulator inserted into the nerve cuff, in any appropriate manner.
In some variations, a sizing tool may be used to measure the vagus (e.g., diameter) to select an appropriate microstimulator and cuff (e.g., small, medium, large). In some variations of the method, as described above, an oversized cuff may be used. The nerve cuff is then placed under the nerve with the opening into the nerve cuff facing the surgeon (
The invention may be embodied in other specific forms without departing from the essential attributes thereof; therefore, the illustrated embodiments should be considered in all respects as illustrative and not restrictive. The claims provided herein are to ensure adequacy of the present application for establishing foreign priority and for no other purpose.
This application is a continuation of U.S. patent application Ser. No. 14/931,711, filed Nov. 3, 2015, titled “NERVE CUFF WITH POCKET FOR LEADLESS STIMULATOR,” now U.S. Pat. No. 9,700,716, which is a continuation of U.S. patent application Ser. No. 14/536,461, filed Nov. 7, 2014, titled “NERVE CUFF WITH POCKET FOR LEADLESS STIMULATOR,” now U.S. Pat. No. 9,174,041, which is a divisional of U.S. patent application Ser. No. 12/797,452, filed Jun. 9, 2010, titled “NERVE CUFF WITH POCKET FOR LEADLESS STIMULATOR, now U.S. Pat. No. 8,886,339, which claims the benefit under 35 U.S.C. § 119 of U.S. Provisional Patent Application No. 61/185,494, filed on Jun. 9, 2009, titled “NERVE CUFF WITH POCKET FOR LEADLESS STIMULATOR,” each of which is herein incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
2164121 | Pescador | Jun 1939 | A |
3363623 | Atwell | Jan 1968 | A |
3631534 | Hirota et al. | Dec 1971 | A |
4073296 | McCall | Feb 1978 | A |
4098277 | Mendell | Jul 1978 | A |
4305402 | Katims | Dec 1981 | A |
4503863 | Katims | Mar 1985 | A |
4573481 | Bullara | Mar 1986 | A |
4590946 | Loeb | May 1986 | A |
4632095 | Libin | Dec 1986 | A |
4649936 | Ungar et al. | Mar 1987 | A |
4702254 | Zabara | Oct 1987 | A |
4840793 | Todd, III et al. | Jun 1989 | A |
4867164 | Zabara | Sep 1989 | A |
4929734 | Coughenour et al. | May 1990 | A |
4930516 | Alfano et al. | Jun 1990 | A |
4935234 | Todd, III et al. | Jun 1990 | A |
4979511 | Terry, Jr. | Dec 1990 | A |
4991578 | Cohen | Feb 1991 | A |
5019648 | Schlossman et al. | May 1991 | A |
5025807 | Zabara | Jun 1991 | A |
5038781 | Lynch | Aug 1991 | A |
5049659 | Cantor et al. | Sep 1991 | A |
5073560 | Wu et al. | Dec 1991 | A |
5106853 | Showell et al. | Apr 1992 | A |
5111815 | Mower | May 1992 | A |
5154172 | Terry, Jr. et al. | Oct 1992 | A |
5175166 | Dunbar et al. | Dec 1992 | A |
5179950 | Stanislaw | Jan 1993 | A |
5186170 | Varrichio et al. | Feb 1993 | A |
5188104 | Wernicke et al. | Feb 1993 | A |
5203326 | Collins | Apr 1993 | A |
5205285 | Baker, Jr. | Apr 1993 | A |
5215086 | Terry, Jr. et al. | Jun 1993 | A |
5215089 | Baker, Jr. | Jun 1993 | A |
5222494 | Baker, Jr. | Jun 1993 | A |
5231988 | Wernicke et al. | Aug 1993 | A |
5235980 | Varrichio et al. | Aug 1993 | A |
5237991 | Baker et al. | Aug 1993 | A |
5251634 | Weinberg | Oct 1993 | A |
5263480 | Wernicke et al. | Nov 1993 | A |
5269303 | Wernicke et al. | Dec 1993 | A |
5299569 | Wernicke et al. | Apr 1994 | A |
5304206 | Baker, Jr. et al. | Apr 1994 | A |
5330507 | Schwartz | Jul 1994 | A |
5330515 | Rutecki et al. | Jul 1994 | A |
5335657 | Terry, Jr. et al. | Aug 1994 | A |
5344438 | Testerman et al. | Sep 1994 | A |
5351394 | Weinberg | Oct 1994 | A |
5403845 | Dunbar et al. | Apr 1995 | A |
5458625 | Kendall | Oct 1995 | A |
5472841 | Jayasena et al. | Dec 1995 | A |
5487756 | Kallesoe et al. | Jan 1996 | A |
5496938 | Gold et al. | Mar 1996 | A |
5503978 | Schneider et al. | Apr 1996 | A |
5531778 | Maschino et al. | Jul 1996 | A |
5540730 | Terry, Jr. et al. | Jul 1996 | A |
5540734 | Zabara | Jul 1996 | A |
5567588 | Gold et al. | Oct 1996 | A |
5567724 | Kelleher et al. | Oct 1996 | A |
5571150 | Wernicke et al. | Nov 1996 | A |
5580737 | Polisky et al. | Dec 1996 | A |
5582981 | Toole et al. | Dec 1996 | A |
5604231 | Smith et al. | Feb 1997 | A |
5607459 | Paul et al. | Mar 1997 | A |
5611350 | John | Mar 1997 | A |
5618818 | Ojo et al. | Apr 1997 | A |
5629285 | Black et al. | May 1997 | A |
5637459 | Burke et al. | Jun 1997 | A |
5651378 | Matheny et al. | Jul 1997 | A |
5654151 | Allen et al. | Aug 1997 | A |
5683867 | Biesecker et al. | Nov 1997 | A |
5690681 | Geddes et al. | Nov 1997 | A |
5700282 | Zabara | Dec 1997 | A |
5705337 | Gold et al. | Jan 1998 | A |
5707400 | Terry, Jr. et al. | Jan 1998 | A |
5709853 | Iino et al. | Jan 1998 | A |
5712375 | Jensen et al. | Jan 1998 | A |
5718912 | Thompson et al. | Feb 1998 | A |
5726017 | Lochrie et al. | Mar 1998 | A |
5726179 | Messer, Jr. et al. | Mar 1998 | A |
5727556 | Weth et al. | Mar 1998 | A |
5733255 | Dinh et al. | Mar 1998 | A |
5741802 | Kern et al. | Apr 1998 | A |
5773598 | Burke et al. | Jun 1998 | A |
5786462 | Schneider et al. | Jul 1998 | A |
5788656 | Mino | Aug 1998 | A |
5792210 | Wamubu et al. | Aug 1998 | A |
5853005 | Scanlon | Dec 1998 | A |
5854289 | Bianchi et al. | Dec 1998 | A |
5902814 | Gordon et al. | May 1999 | A |
5913876 | Taylor et al. | Jun 1999 | A |
5916239 | Geddes et al. | Jun 1999 | A |
5919216 | Houben et al. | Jul 1999 | A |
5928272 | Adkins et al. | Jul 1999 | A |
5964794 | Bolz et al. | Oct 1999 | A |
5977144 | Meyer et al. | Nov 1999 | A |
5994330 | El Khoury | Nov 1999 | A |
6002964 | Feler et al. | Dec 1999 | A |
6006134 | Hill et al. | Dec 1999 | A |
6017891 | Eibl et al. | Jan 2000 | A |
6028186 | Tasset et al. | Feb 2000 | A |
6051017 | Loeb et al. | Apr 2000 | A |
6083696 | Biesecker et al. | Jul 2000 | A |
6083905 | Voorberg et al. | Jul 2000 | A |
6096728 | Collins et al. | Aug 2000 | A |
6104956 | Naritoku et al. | Aug 2000 | A |
6110900 | Gold et al. | Aug 2000 | A |
6110914 | Phillips et al. | Aug 2000 | A |
6117837 | Tracey et al. | Sep 2000 | A |
6124449 | Gold et al. | Sep 2000 | A |
6127119 | Stephens et al. | Oct 2000 | A |
6140490 | Biesecker et al. | Oct 2000 | A |
6141590 | Renirie et al. | Oct 2000 | A |
6147204 | Gold et al. | Nov 2000 | A |
6159145 | Satoh | Dec 2000 | A |
6164284 | Schulman et al. | Dec 2000 | A |
6166048 | Bencherif | Dec 2000 | A |
6168778 | Janjic et al. | Jan 2001 | B1 |
6171795 | Korman et al. | Jan 2001 | B1 |
6205359 | Boveja | Mar 2001 | B1 |
6208894 | Schulman et al. | Mar 2001 | B1 |
6208902 | Boveja | Mar 2001 | B1 |
6210321 | Di Mino et al. | Apr 2001 | B1 |
6224862 | Turecek et al. | May 2001 | B1 |
6233488 | Hess | May 2001 | B1 |
6266564 | Hill et al. | Jul 2001 | B1 |
6269270 | Boveja | Jul 2001 | B1 |
6304775 | Iasemidis et al. | Oct 2001 | B1 |
6308104 | Taylor et al. | Oct 2001 | B1 |
6337997 | Rise | Jan 2002 | B1 |
6339725 | Naritoku et al. | Jan 2002 | B1 |
6341236 | Osorio et al. | Jan 2002 | B1 |
6356787 | Rezai et al. | Mar 2002 | B1 |
6356788 | Boveja | Mar 2002 | B2 |
6381499 | Taylor et al. | Apr 2002 | B1 |
6405732 | Edwards et al. | Jun 2002 | B1 |
6407095 | Lochead et al. | Jun 2002 | B1 |
6428484 | Battmer et al. | Aug 2002 | B1 |
6429217 | Puskas | Aug 2002 | B1 |
6447443 | Keogh et al. | Sep 2002 | B1 |
6449507 | Hill et al. | Sep 2002 | B1 |
6473644 | Terry, Jr. et al. | Oct 2002 | B1 |
6479523 | Puskas | Nov 2002 | B1 |
6487446 | Hill et al. | Nov 2002 | B1 |
6511500 | Rahme | Jan 2003 | B1 |
6528529 | Brann et al. | Mar 2003 | B1 |
6532388 | Hill et al. | Mar 2003 | B1 |
6542774 | Hill et al. | Apr 2003 | B2 |
6556868 | Naritoku et al. | Apr 2003 | B2 |
6564102 | Boveja | May 2003 | B1 |
6587719 | Barrett et al. | Jul 2003 | B1 |
6587727 | Osorio et al. | Jul 2003 | B2 |
6600956 | Maschino et al. | Jul 2003 | B2 |
6602891 | Messer et al. | Aug 2003 | B2 |
6609025 | Barrett et al. | Aug 2003 | B2 |
6610713 | Tracey | Aug 2003 | B2 |
6611715 | Boveja | Aug 2003 | B1 |
6615081 | Boveja | Sep 2003 | B1 |
6615085 | Boveja | Sep 2003 | B1 |
6622038 | Barrett et al. | Sep 2003 | B2 |
6622041 | Terry, Jr. et al. | Sep 2003 | B2 |
6622047 | Barrett et al. | Sep 2003 | B2 |
6628987 | Hill et al. | Sep 2003 | B1 |
6633779 | Schuler et al. | Oct 2003 | B1 |
6656960 | Puskas | Dec 2003 | B2 |
6668191 | Boveja | Dec 2003 | B1 |
6671556 | Osorio et al. | Dec 2003 | B2 |
6684105 | Cohen et al. | Jan 2004 | B2 |
6690973 | Hill et al. | Feb 2004 | B2 |
6718208 | Hill et al. | Apr 2004 | B2 |
6721603 | Zabara et al. | Apr 2004 | B2 |
6735471 | Hill et al. | May 2004 | B2 |
6735475 | Whitehurst et al. | May 2004 | B1 |
6760626 | Boveja | Jul 2004 | B1 |
6778854 | Puskas | Aug 2004 | B2 |
6804558 | Haller et al. | Oct 2004 | B2 |
RE38654 | Hill et al. | Nov 2004 | E |
6826428 | Chen et al. | Nov 2004 | B1 |
6832114 | Whitehurst et al. | Dec 2004 | B1 |
6838471 | Tracey | Jan 2005 | B2 |
RE38705 | Hill et al. | Feb 2005 | E |
6879859 | Boveja | Apr 2005 | B1 |
6885888 | Rezai | Apr 2005 | B2 |
6901294 | Whitehurst et al. | May 2005 | B1 |
6904318 | Hill et al. | Jun 2005 | B2 |
6920357 | Osorio et al. | Jul 2005 | B2 |
6928320 | King | Aug 2005 | B2 |
6934583 | Weinberg et al. | Aug 2005 | B2 |
6937903 | Schuler et al. | Aug 2005 | B2 |
6961618 | Osorio et al. | Nov 2005 | B2 |
6978787 | Broniatowski | Dec 2005 | B1 |
7011638 | Schuler et al. | Mar 2006 | B2 |
7054686 | MacDonald | May 2006 | B2 |
7054692 | Whitehurst et al. | May 2006 | B1 |
7058447 | Hill et al. | Jun 2006 | B2 |
7062320 | Ehlinger, Jr. | Jun 2006 | B2 |
7069082 | Lindenthaler | Jun 2006 | B2 |
7072720 | Puskas | Jul 2006 | B2 |
7076307 | Boveja et al. | Jul 2006 | B2 |
7142910 | Puskas | Nov 2006 | B2 |
7142917 | Fukui | Nov 2006 | B2 |
7149574 | Yun et al. | Dec 2006 | B2 |
7155279 | Whitehurst et al. | Dec 2006 | B2 |
7155284 | Whitehurst et al. | Dec 2006 | B1 |
7167750 | Knudson et al. | Jan 2007 | B2 |
7167751 | Whitehurst et al. | Jan 2007 | B1 |
7174218 | Kuzma | Feb 2007 | B1 |
7184828 | Hill et al. | Feb 2007 | B2 |
7184829 | Hill et al. | Feb 2007 | B2 |
7191012 | Boveja et al. | Mar 2007 | B2 |
7204815 | Connor | Apr 2007 | B2 |
7209787 | DiLorenzo | Apr 2007 | B2 |
7225019 | Jahns et al. | May 2007 | B2 |
7228167 | Kara et al. | Jun 2007 | B2 |
7238715 | Tracey et al. | Jul 2007 | B2 |
7242984 | DiLorenzo | Jul 2007 | B2 |
7269457 | Shafer et al. | Sep 2007 | B2 |
7345178 | Nunes et al. | Mar 2008 | B2 |
7389145 | Kilgore et al. | Jun 2008 | B2 |
7467016 | Colborn | Dec 2008 | B2 |
7544497 | Sinclair et al. | Jun 2009 | B2 |
7561918 | Armstrong et al. | Jul 2009 | B2 |
7711432 | Thimineur et al. | May 2010 | B2 |
7729760 | Patel et al. | Jun 2010 | B2 |
7751891 | Armstrong et al. | Jul 2010 | B2 |
7776326 | Milbrandt et al. | Aug 2010 | B2 |
7797058 | Mrva et al. | Sep 2010 | B2 |
7819883 | Westlund et al. | Oct 2010 | B2 |
7822486 | Foster et al. | Oct 2010 | B2 |
7829556 | Bemis et al. | Nov 2010 | B2 |
7869885 | Begnaud et al. | Jan 2011 | B2 |
7937145 | Dobak | May 2011 | B2 |
7962220 | Kolafa et al. | Jun 2011 | B2 |
7974701 | Armstrong | Jul 2011 | B2 |
7974707 | Inman | Jul 2011 | B2 |
7996088 | Marrosu et al. | Aug 2011 | B2 |
7996092 | Mrva et al. | Aug 2011 | B2 |
8019419 | Panescu et al. | Sep 2011 | B1 |
8060208 | Kilgore et al. | Nov 2011 | B2 |
8103349 | Donders et al. | Jan 2012 | B2 |
8165668 | Dacey, Jr. et al. | Apr 2012 | B2 |
8180446 | Dacey, Jr. et al. | May 2012 | B2 |
8195287 | Dacey, Jr. et al. | Jun 2012 | B2 |
8214056 | Hoffer et al. | Jul 2012 | B2 |
8233982 | Libbus | Jul 2012 | B2 |
8391970 | Tracey et al. | Mar 2013 | B2 |
8412338 | Faltys | Apr 2013 | B2 |
8612002 | Faltys et al. | Dec 2013 | B2 |
8729129 | Tracey et al. | May 2014 | B2 |
8788034 | Levine et al. | Jul 2014 | B2 |
8843210 | Simon et al. | Sep 2014 | B2 |
8855767 | Faltys et al. | Oct 2014 | B2 |
8886339 | Faltys et al. | Nov 2014 | B2 |
8914114 | Tracey et al. | Dec 2014 | B2 |
8918178 | Simon et al. | Dec 2014 | B2 |
8983628 | Simon et al. | Mar 2015 | B2 |
8983629 | Simon et al. | Mar 2015 | B2 |
8996116 | Faltys et al. | Mar 2015 | B2 |
9162064 | Faltys et al. | Oct 2015 | B2 |
9174041 | Faltys et al. | Nov 2015 | B2 |
9211409 | Tracey et al. | Dec 2015 | B2 |
9211410 | Levine et al. | Dec 2015 | B2 |
9254383 | Simon et al. | Feb 2016 | B2 |
9403001 | Simon et al. | Aug 2016 | B2 |
9572983 | Levine et al. | Feb 2017 | B2 |
9662490 | Tracey et al. | May 2017 | B2 |
9700716 | Faltys | Jul 2017 | B2 |
20010002441 | Boveja | May 2001 | A1 |
20020026141 | Houben et al. | Feb 2002 | A1 |
20020040035 | Myers et al. | Apr 2002 | A1 |
20020077675 | Greenstein | Jun 2002 | A1 |
20020086871 | O'Neill et al. | Jul 2002 | A1 |
20020095139 | Keogh et al. | Jul 2002 | A1 |
20020099417 | Naritoku et al. | Jul 2002 | A1 |
20020138075 | Edwards et al. | Sep 2002 | A1 |
20020138109 | Keogh et al. | Sep 2002 | A1 |
20020193859 | Schulman et al. | Dec 2002 | A1 |
20020198570 | Puskas | Dec 2002 | A1 |
20030018367 | DiLorenzo | Jan 2003 | A1 |
20030045909 | Gross et al. | Mar 2003 | A1 |
20030088301 | King | May 2003 | A1 |
20030191404 | Klein | Oct 2003 | A1 |
20030194752 | Anderson et al. | Oct 2003 | A1 |
20030195578 | Perron et al. | Oct 2003 | A1 |
20030212440 | Boveja | Nov 2003 | A1 |
20030229380 | Adams et al. | Dec 2003 | A1 |
20030236557 | Whitehurst et al. | Dec 2003 | A1 |
20030236558 | Whitehurst et al. | Dec 2003 | A1 |
20040002546 | Altschuler | Jan 2004 | A1 |
20040015202 | Chandler et al. | Jan 2004 | A1 |
20040015205 | Whitehurst et al. | Jan 2004 | A1 |
20040024422 | Hill et al. | Feb 2004 | A1 |
20040024428 | Barrett et al. | Feb 2004 | A1 |
20040024439 | Riso | Feb 2004 | A1 |
20040030362 | Hill et al. | Feb 2004 | A1 |
20040039427 | Barrett et al. | Feb 2004 | A1 |
20040048795 | Ivanova et al. | Mar 2004 | A1 |
20040049121 | Yaron | Mar 2004 | A1 |
20040049240 | Gerber et al. | Mar 2004 | A1 |
20040059383 | Puskas | Mar 2004 | A1 |
20040111139 | McCreery et al. | Jun 2004 | A1 |
20040138517 | Osorio et al. | Jul 2004 | A1 |
20040138518 | Rise et al. | Jul 2004 | A1 |
20040138536 | Frei et al. | Jul 2004 | A1 |
20040146949 | Tan et al. | Jul 2004 | A1 |
20040153127 | Gordon et al. | Aug 2004 | A1 |
20040158119 | Osorio et al. | Aug 2004 | A1 |
20040162584 | Hill et al. | Aug 2004 | A1 |
20040172074 | Yoshihito | Sep 2004 | A1 |
20040172085 | Knudson et al. | Sep 2004 | A1 |
20040172086 | Knudson et al. | Sep 2004 | A1 |
20040172088 | Knudson et al. | Sep 2004 | A1 |
20040172094 | Cohen et al. | Sep 2004 | A1 |
20040176812 | Knudson et al. | Sep 2004 | A1 |
20040178706 | D'Orso | Sep 2004 | A1 |
20040193231 | David et al. | Sep 2004 | A1 |
20040199209 | Hill et al. | Oct 2004 | A1 |
20040199210 | Shelchuk | Oct 2004 | A1 |
20040204355 | Tracey et al. | Oct 2004 | A1 |
20040215272 | Haubrich et al. | Oct 2004 | A1 |
20040215287 | Swoyer et al. | Oct 2004 | A1 |
20040236381 | Dinsmoor et al. | Nov 2004 | A1 |
20040236382 | Dinsmoor et al. | Nov 2004 | A1 |
20040240691 | Grafenberg | Dec 2004 | A1 |
20040243182 | Cohen et al. | Dec 2004 | A1 |
20040254612 | Ezra et al. | Dec 2004 | A1 |
20040267152 | Pineda | Dec 2004 | A1 |
20050021092 | Yun et al. | Jan 2005 | A1 |
20050021101 | Chen et al. | Jan 2005 | A1 |
20050027328 | Greenstein | Feb 2005 | A1 |
20050043774 | Devlin et al. | Feb 2005 | A1 |
20050049655 | Boveja et al. | Mar 2005 | A1 |
20050065553 | Ben Ezra et al. | Mar 2005 | A1 |
20050065573 | Rezai | Mar 2005 | A1 |
20050065575 | Dobak | Mar 2005 | A1 |
20050070970 | Knudson et al. | Mar 2005 | A1 |
20050070974 | Knudson et al. | Mar 2005 | A1 |
20050075701 | Shafer | Apr 2005 | A1 |
20050075702 | Shafer | Apr 2005 | A1 |
20050095246 | Shafer | May 2005 | A1 |
20050096707 | Hill et al. | May 2005 | A1 |
20050103351 | Stomberg et al. | May 2005 | A1 |
20050131467 | Boveja | Jun 2005 | A1 |
20050131486 | Boveja et al. | Jun 2005 | A1 |
20050131487 | Boveja | Jun 2005 | A1 |
20050131493 | Boveja et al. | Jun 2005 | A1 |
20050137644 | Boveja et al. | Jun 2005 | A1 |
20050137645 | Voipio et al. | Jun 2005 | A1 |
20050143781 | Carbunaru et al. | Jun 2005 | A1 |
20050143787 | Boveja et al. | Jun 2005 | A1 |
20050149126 | Libbus | Jul 2005 | A1 |
20050149129 | Libbus et al. | Jul 2005 | A1 |
20050149131 | Libbus et al. | Jul 2005 | A1 |
20050153885 | Yun et al. | Jul 2005 | A1 |
20050154425 | Boveja et al. | Jul 2005 | A1 |
20050154426 | Boveja et al. | Jul 2005 | A1 |
20050165458 | Boveja et al. | Jul 2005 | A1 |
20050177200 | George et al. | Aug 2005 | A1 |
20050182288 | Zabara | Aug 2005 | A1 |
20050182467 | Hunter et al. | Aug 2005 | A1 |
20050187584 | Denker et al. | Aug 2005 | A1 |
20050187586 | David et al. | Aug 2005 | A1 |
20050187590 | Boveja et al. | Aug 2005 | A1 |
20050191661 | Gatanaga et al. | Sep 2005 | A1 |
20050192644 | Boveja et al. | Sep 2005 | A1 |
20050197600 | Schuler et al. | Sep 2005 | A1 |
20050197675 | David et al. | Sep 2005 | A1 |
20050197678 | Boveja et al. | Sep 2005 | A1 |
20050203501 | Aldrich et al. | Sep 2005 | A1 |
20050209654 | Boveja et al. | Sep 2005 | A1 |
20050216064 | Heruth et al. | Sep 2005 | A1 |
20050216070 | Boveja et al. | Sep 2005 | A1 |
20050216071 | Devlin et al. | Sep 2005 | A1 |
20050240229 | Whitehurst et al. | Oct 2005 | A1 |
20050240231 | Aldrich et al. | Oct 2005 | A1 |
20050240241 | Yun et al. | Oct 2005 | A1 |
20050240242 | DiLorenzo | Oct 2005 | A1 |
20050251220 | Barrett et al. | Nov 2005 | A1 |
20050251222 | Barrett et al. | Nov 2005 | A1 |
20050267542 | David et al. | Dec 2005 | A1 |
20050267547 | Knudson et al. | Dec 2005 | A1 |
20050283198 | Haubrich et al. | Dec 2005 | A1 |
20060009815 | Boveja et al. | Jan 2006 | A1 |
20060015151 | Aldrich | Jan 2006 | A1 |
20060025828 | Armstrong et al. | Feb 2006 | A1 |
20060036293 | Whitehurst et al. | Feb 2006 | A1 |
20060052657 | Zabara | Mar 2006 | A9 |
20060052831 | Fukui | Mar 2006 | A1 |
20060052836 | Kim et al. | Mar 2006 | A1 |
20060058851 | Cigaina | Mar 2006 | A1 |
20060064137 | Stone | Mar 2006 | A1 |
20060064139 | Chung et al. | Mar 2006 | A1 |
20060074450 | Boveja et al. | Apr 2006 | A1 |
20060074473 | Gertner | Apr 2006 | A1 |
20060079936 | Boveja et al. | Apr 2006 | A1 |
20060085046 | Rezai et al. | Apr 2006 | A1 |
20060095081 | Zhou et al. | May 2006 | A1 |
20060095090 | De Ridder | May 2006 | A1 |
20060100668 | Ben-David et al. | May 2006 | A1 |
20060106755 | Stuhec | May 2006 | A1 |
20060111644 | Guttag et al. | May 2006 | A1 |
20060111754 | Rezai et al. | May 2006 | A1 |
20060111755 | Stone et al. | May 2006 | A1 |
20060116739 | Betser et al. | Jun 2006 | A1 |
20060122675 | Libbus et al. | Jun 2006 | A1 |
20060129200 | Kurokawa | Jun 2006 | A1 |
20060129202 | Armstrong | Jun 2006 | A1 |
20060135998 | Libbus et al. | Jun 2006 | A1 |
20060142802 | Armstrong | Jun 2006 | A1 |
20060142822 | Tulgar | Jun 2006 | A1 |
20060149337 | John | Jul 2006 | A1 |
20060155495 | Osorio et al. | Jul 2006 | A1 |
20060161216 | John et al. | Jul 2006 | A1 |
20060161217 | Jaax et al. | Jul 2006 | A1 |
20060167497 | Armstrong et al. | Jul 2006 | A1 |
20060167498 | DiLorenzo | Jul 2006 | A1 |
20060167501 | Ben-David et al. | Jul 2006 | A1 |
20060173493 | Armstrong et al. | Aug 2006 | A1 |
20060173508 | Stone et al. | Aug 2006 | A1 |
20060178691 | Binmoeller | Aug 2006 | A1 |
20060178703 | Huston et al. | Aug 2006 | A1 |
20060178706 | Lisogurski et al. | Aug 2006 | A1 |
20060190044 | Libbus et al. | Aug 2006 | A1 |
20060200208 | Terry, Jr. et al. | Sep 2006 | A1 |
20060200219 | Thrope et al. | Sep 2006 | A1 |
20060206155 | Ben-David et al. | Sep 2006 | A1 |
20060206158 | Wu et al. | Sep 2006 | A1 |
20060229677 | Moffitt et al. | Oct 2006 | A1 |
20060229681 | Fischell | Oct 2006 | A1 |
20060241699 | Libbus et al. | Oct 2006 | A1 |
20060247719 | Maschino et al. | Nov 2006 | A1 |
20060247721 | Maschino et al. | Nov 2006 | A1 |
20060247722 | Maschino et al. | Nov 2006 | A1 |
20060259077 | Pardo et al. | Nov 2006 | A1 |
20060259084 | Zhang et al. | Nov 2006 | A1 |
20060259085 | Zhang et al. | Nov 2006 | A1 |
20060259107 | Caparso et al. | Nov 2006 | A1 |
20060271115 | Ben-Ezra et al. | Nov 2006 | A1 |
20060282121 | Payne et al. | Dec 2006 | A1 |
20060282131 | Caparso et al. | Dec 2006 | A1 |
20060282145 | Caparso et al. | Dec 2006 | A1 |
20060287678 | Shafer | Dec 2006 | A1 |
20060287679 | Stone | Dec 2006 | A1 |
20060292099 | Milburn et al. | Dec 2006 | A1 |
20060293720 | DiLorenzo | Dec 2006 | A1 |
20060293721 | Tarver et al. | Dec 2006 | A1 |
20060293723 | Whitehurst et al. | Dec 2006 | A1 |
20070016262 | Gross et al. | Jan 2007 | A1 |
20070016263 | Armstrong et al. | Jan 2007 | A1 |
20070021785 | Inman et al. | Jan 2007 | A1 |
20070021786 | Parnis et al. | Jan 2007 | A1 |
20070021814 | Inman et al. | Jan 2007 | A1 |
20070025608 | Armstrong | Feb 2007 | A1 |
20070027482 | Parnis et al. | Feb 2007 | A1 |
20070027483 | Maschino et al. | Feb 2007 | A1 |
20070027484 | Guzman et al. | Feb 2007 | A1 |
20070027486 | Armstrong | Feb 2007 | A1 |
20070027492 | Maschino et al. | Feb 2007 | A1 |
20070027496 | Parnis et al. | Feb 2007 | A1 |
20070027497 | Parnis | Feb 2007 | A1 |
20070027498 | Maschino et al. | Feb 2007 | A1 |
20070027499 | Maschino et al. | Feb 2007 | A1 |
20070027500 | Maschino et al. | Feb 2007 | A1 |
20070027504 | Barrett et al. | Feb 2007 | A1 |
20070055324 | Thompson et al. | Mar 2007 | A1 |
20070067004 | Boveja et al. | Mar 2007 | A1 |
20070083242 | Mazgalev et al. | Apr 2007 | A1 |
20070093434 | Rossetti et al. | Apr 2007 | A1 |
20070093870 | Maschino | Apr 2007 | A1 |
20070093875 | Chavan et al. | Apr 2007 | A1 |
20070100263 | Merfeld | May 2007 | A1 |
20070100377 | Armstrong et al. | May 2007 | A1 |
20070100378 | Maschino | May 2007 | A1 |
20070100380 | Fukui | May 2007 | A1 |
20070100392 | Maschino et al. | May 2007 | A1 |
20070106339 | Errico et al. | May 2007 | A1 |
20070112404 | Mann et al. | May 2007 | A1 |
20070118177 | Libbus et al. | May 2007 | A1 |
20070118178 | Fukui | May 2007 | A1 |
20070129767 | Wahlstrand | Jun 2007 | A1 |
20070129780 | Whitehurst et al. | Jun 2007 | A1 |
20070135846 | Knudson et al. | Jun 2007 | A1 |
20070135856 | Knudson et al. | Jun 2007 | A1 |
20070135857 | Knudson et al. | Jun 2007 | A1 |
20070135858 | Knudson et al. | Jun 2007 | A1 |
20070142870 | Knudson et al. | Jun 2007 | A1 |
20070142871 | Libbus et al. | Jun 2007 | A1 |
20070142874 | John | Jun 2007 | A1 |
20070150006 | Libbus et al. | Jun 2007 | A1 |
20070150011 | Meyer et al. | Jun 2007 | A1 |
20070150021 | Chen et al. | Jun 2007 | A1 |
20070150027 | Rogers | Jun 2007 | A1 |
20070156180 | Jaax et al. | Jul 2007 | A1 |
20070198063 | Hunter et al. | Aug 2007 | A1 |
20070239243 | Moffitt et al. | Oct 2007 | A1 |
20070244522 | Overstreet | Oct 2007 | A1 |
20070250145 | Kraus et al. | Oct 2007 | A1 |
20070255320 | Inman et al. | Nov 2007 | A1 |
20070255333 | Giftakis | Nov 2007 | A1 |
20070255339 | Torgerson | Nov 2007 | A1 |
20080021517 | Dietrich | Jan 2008 | A1 |
20080021520 | Dietrich | Jan 2008 | A1 |
20080046055 | Durand et al. | Feb 2008 | A1 |
20080058871 | Libbus et al. | Mar 2008 | A1 |
20080103407 | Bolea et al. | May 2008 | A1 |
20080140138 | Ivanova et al. | Jun 2008 | A1 |
20080183226 | Buras et al. | Jul 2008 | A1 |
20080183246 | Patel et al. | Jul 2008 | A1 |
20080195171 | Sharma | Aug 2008 | A1 |
20080208266 | Lesser et al. | Aug 2008 | A1 |
20080234790 | Bayer et al. | Sep 2008 | A1 |
20080281365 | Tweden et al. | Nov 2008 | A1 |
20080281372 | Libbus et al. | Nov 2008 | A1 |
20090012590 | Inman et al. | Jan 2009 | A1 |
20090048194 | Aerssens et al. | Feb 2009 | A1 |
20090082832 | Carbunaru et al. | Mar 2009 | A1 |
20090088821 | Abrahamson | Apr 2009 | A1 |
20090105782 | Mickle et al. | Apr 2009 | A1 |
20090123521 | Weber et al. | May 2009 | A1 |
20090125079 | Armstrong et al. | May 2009 | A1 |
20090143831 | Huston et al. | Jun 2009 | A1 |
20090171405 | Craig | Jul 2009 | A1 |
20090177112 | Gharib et al. | Jul 2009 | A1 |
20090187231 | Errico et al. | Jul 2009 | A1 |
20090248097 | Tracey et al. | Oct 2009 | A1 |
20090254143 | Tweden et al. | Oct 2009 | A1 |
20090275997 | Faltys et al. | Nov 2009 | A1 |
20090276019 | Perez et al. | Nov 2009 | A1 |
20090281593 | Errico et al. | Nov 2009 | A9 |
20090312817 | Hogle et al. | Dec 2009 | A1 |
20100003656 | Kilgard et al. | Jan 2010 | A1 |
20100010571 | Skelton et al. | Jan 2010 | A1 |
20100010581 | Goetz et al. | Jan 2010 | A1 |
20100010603 | Ben-David et al. | Jan 2010 | A1 |
20100016746 | Hampton et al. | Jan 2010 | A1 |
20100042186 | Ben-David et al. | Feb 2010 | A1 |
20100063563 | Craig | Mar 2010 | A1 |
20100074934 | Hunter | Mar 2010 | A1 |
20100191304 | Scott | Jul 2010 | A1 |
20100215632 | Boss et al. | Aug 2010 | A1 |
20100241183 | DiLorenzo | Sep 2010 | A1 |
20100249859 | DiLorenzo | Sep 2010 | A1 |
20100280562 | Pi et al. | Nov 2010 | A1 |
20100280569 | Bobillier et al. | Nov 2010 | A1 |
20110004266 | Sharma | Jan 2011 | A1 |
20110054569 | Zitnik et al. | Mar 2011 | A1 |
20110066208 | Pasricha et al. | Mar 2011 | A1 |
20110082515 | Libbus et al. | Apr 2011 | A1 |
20110092882 | Firlik et al. | Apr 2011 | A1 |
20110144717 | Burton et al. | Jun 2011 | A1 |
20110224749 | Ben-David et al. | Sep 2011 | A1 |
20110307027 | Sharma et al. | Dec 2011 | A1 |
20120065706 | Vallapureddy et al. | Mar 2012 | A1 |
20120185020 | Simon et al. | Jul 2012 | A1 |
20130066392 | Simon et al. | Mar 2013 | A1 |
20130066395 | Simon et al. | Mar 2013 | A1 |
20130079834 | Levine | Mar 2013 | A1 |
20130317580 | Simon et al. | Nov 2013 | A1 |
20140046407 | Ben-Ezra et al. | Feb 2014 | A1 |
20150100100 | Tracey et al. | Apr 2015 | A1 |
20150241447 | Zitnik et al. | Aug 2015 | A1 |
20160038745 | Faltys et al. | Feb 2016 | A1 |
20160067497 | Levine et al. | Mar 2016 | A1 |
20160096017 | Levine et al. | Apr 2016 | A1 |
20160114165 | Levine et al. | Apr 2016 | A1 |
20160250097 | Tracey et al. | Sep 2016 | A9 |
20160331952 | Faltys et al. | Nov 2016 | A1 |
20160367808 | Simon et al. | Dec 2016 | A9 |
20170113044 | Levine et al. | Apr 2017 | A1 |
20170197076 | Faltys et al. | Jul 2017 | A1 |
20170202467 | Zitnik et al. | Jul 2017 | A1 |
20170203103 | Levine et al. | Jul 2017 | A1 |
20170209705 | Faltys et al. | Jul 2017 | A1 |
20170266448 | Tracey et al. | Sep 2017 | A1 |
20180021217 | Tracey et al. | Jan 2018 | A1 |
20180117320 | Levine et al. | May 2018 | A1 |
Number | Date | Country |
---|---|---|
201230913 | May 2009 | CN |
101528303 | Sep 2009 | CN |
101578067 | Nov 2009 | CN |
101868280 | Oct 2010 | CN |
2628045 | Jan 1977 | DE |
3736664 | May 1989 | DE |
20316509 | Apr 2004 | DE |
0438510 | Aug 1996 | EP |
0726791 | Jun 2000 | EP |
1001827 | Jan 2004 | EP |
2213330 | Aug 2010 | EP |
2073896 | Oct 2011 | EP |
04133 | Feb 1910 | GB |
WO9301862 | Feb 1993 | WO |
WO9730998 | Aug 1997 | WO |
WO9820868 | May 1998 | WO |
WO0027381 | May 2000 | WO |
WO0047104 | Aug 2000 | WO |
WO0100273 | Jan 2001 | WO |
WO0108617 | Feb 2001 | WO |
WO0189526 | Nov 2001 | WO |
WO0244176 | Jun 2002 | WO |
WO02057275 | Jul 2002 | WO |
WO03072135 | Sep 2003 | WO |
WO2004000413 | Dec 2003 | WO |
WO2004064918 | Aug 2004 | WO |
WO2006073484 | Jul 2006 | WO |
WO2006076681 | Jul 2006 | WO |
WO2007133718 | Nov 2007 | WO |
WO2010005482 | Jan 2010 | WO |
WO2010067360 | Jun 2010 | WO |
WO2010118035 | Oct 2010 | WO |
Entry |
---|
US 6,184,239, 02/2001, Puskas (withdrawn) |
Abraham, Coagulation abnormalities in acute lung injury and sepsis, Am. J. Respir. Cell Mol. Biol., vol. 22(4), pp. 401-404, Apr. 2000. |
Aekerlund et al., Anti-inflammatory effects of a new tumour necrosis factor-alpha (TNF-Alpha) inhibitor (CNI-1493) in collagen-induced arthritis (CIA) in rats, Clinical & Experimental Immunology, vol. 115, No. 1, pp. 32-41, Jan. 1, 1999. |
Antonica, A., et al., Vagal control of lymphocyte release from rat thymus, J. Auton. Nerv. Syst., vol. 48(3), pp. 187-197, Aug. 1994. |
Asakura et al., Non-surgical therapy for ulcerative colitis, Nippon Geka Gakkai Zasshi, vol. 98, No. 4, pp. 431-437, Apr. 1997 (abstract only). |
Beliavskaia et al., “On the effects of prolonged stimulation of the peripheral segment of the vagus nerve . . . ,” Fiziologicheskii Zhurnal SSSR Imeni I.M. Sechenova., vol. 52(11); p. 1315-1321, Nov. 1966. |
Ben-Noun et al.; Neck circumference as a simple screening measure for identifying overweight and obese patients; Obesity Research; vol. 9; No. 8; pp. 470-477; Aug. 8, 2001. |
Benoist, et al., “Mast cells in autoimmune disease” Nature., vol. 420(19): pp. 875-878, Dec. 2002. |
Benthem et al.; Parasympathetic inhibition of sympathetic neural activity to the pancreas; Am.J.Physiol Endocrinol.Metab; 280(2); pp. E378-E381; Feb. 2001. |
Bernik et al., Vagus nerve stimulation attenuates cardiac TNF production in endotoxic shock, (supplemental to SHOCK, vol. 15, 2001, Injury, inflammation and sepsis: laboratory and clinical approaches, SHOCK, Abstracts, 24th Annual Conference on Shock, Marco Island, FL, Jun. 9-12, 2001), Abstract No. 81. |
Bernik et al., Vagus nerve stimulation attenuates endotoxic shock and cardiac TNF production, 87th Clinical Congress of the American College of Surgeons, New Orleans, LA, Oct. 9, 2001. |
Bernik et al., Vagus nerve stimulation attenuates LPS-induced cardiac TNF production and myocardial depression IN shock, New York Surgical Society, New York, NY, Apr. 11, 2001. |
Bernik, et al., Pharmacological stimulation of the cholinergic anti-inflammatory pathway, The Journal of Experimental Medicine, vol. 195, No. 6, pp. 781-788, Mar. 18, 2002. |
Besedovsky, H., et al., Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones, Science, vol. 233, No. 4764, pp. 652-654, Aug. 1986. |
Bhattacharya, S.K. et al., Central muscarinic receptor subtypes and carrageenin-induced paw oedema in rats, Res. Esp. Med. vol. 191(1), pp. 65-76, Dec. 1991. |
Bianchi et al., Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone, Journal of Experimental Medicine, vol. 183, pp. 927-936, Mar. 1996. |
Biggio et al.; Chronic vagus nerve stimulation induces neuronal plasticity in the rat hippocampus; Int. J. Neurpsychopharmacol.; vol. 12; No. 9; pp. 1209-1221; Oct. 2009. |
Blackwell, T. S. et al., Sepsis and cytokines: current status, Br. J. Anaesth., vol. 77(1), pp. 110-117, Jul. 1996. |
Blum, A. et al., Role of cytokines in heart failure, Am. Heart J., vol. 135(2), pp. 181-186, Feb. 1998. |
Boldyreff, Gastric and intestinal mucus, its properties and physiological importance, Acta Medica Scandinavica (journal), vol. 89, Issue 1-2, pp. 1-14, Jan./Dec. 1936. |
Borovikova et al., Acetylcholine inhibition of immune response to bacterial endotoxin in human macrophages, Abstracts, Society for Neuroscience, 29th Annual Meeting, Miami Beach, FL, (Abs. No. 624.6); Oct. 23-28, 1999. |
Borovikova et al., Efferent vagus nerve activity attenuates cytokine-mediated inflammation, Society for Neuroscience Abstracts, vol. 26, No. 102, Nov. 4-9, 2000 (abstract only). |
Borovikova et al., Intracerebroventricular CNI-1493 prevents LPS-induced hypotension and peak serum TNF at a four-log lower dose than systemic treatment, 21st Annual Conference on Shock, San Antonio, TX, Jun. 14-17, 1998, Abstract No. 86. |
Borovikova et al., Role of the efferent vagus nerve signaling in the regulation of the innate immune response to LPS, (supplemental to SHOCK, vol. 13, 2000, Molecular, cellular, and systemic pathobiological aspects and therapeutic approaches, abstracts, 5th World Congress on Trauma, Shock inflammation and sepsis-pathophysiology, immune consequences and therapy, Feb. 29, 2000-Mar. 4, 2000, Munich, DE), Abstract No. 166. |
Borovikova et al., Role of the vagus nerve in the anti-inflammatory effects of CNI-1493, the FASEB journal, vol. 14, No. 4, 2000 (Experimental Biology 2000, San Diego, CA, Apr. 15-18, 2000, Abstract No. 97.9). |
Borovikova et al., Vagotomy blocks the protective effects of I.C.V. CNI-1493 against LPS-induced shock, (Supplemental to SHOCK, vol. 11, 1999, Molecular, cellular, and systemic pathobioloigal aspects and therapeutic approaches, abstacts and program, Fourth International Shock Congress and 22nd Annual Conference on Shock, Philadelphia, PA, Jun. 12-16, 1999), Abstract No. 277. |
Borovikova, L. V., et al., Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation, Autonomic Neuroscience, vol. 85, No. 1-3, pp. 141-147, Dec. 20, 2000. |
Borovikova, L. V., et al., Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin, Nature, vol. 405, No. 6785: pp. 458-462, May 25, 2000. |
Bulloch et al.; Characterization of choline O-acetyltransferase (ChAT) in the BALB/C mouse spleen; Int.J.Neurosci.; 76(1-2); pp. 141-149; May 1994. |
Bumgardner, G. L. et al., Transplantation and cytokines, Seminars in Liver Disease, vol. 19, No. 2, Thieme Medical Publishers; pp. 189-204, © 1999. |
Burke et al., Bent pseudoknots and novel RNA inhibitors of type 1 human immunodeficiency virus (HIV-1) reverse transcriptase, J. Mol. Biol., vol. 264(4); pp. 650-666, Dec. 1996. |
Bushby et al; Centiles for adult head circumference; Archives of Disease in Childhood; vol. 67(10); pp. 1286-1287; Oct. 1992. |
Cano et al.; Characterization of the central nervous system innervation of the rat spleen using viral transneuronal tracing; J.Comp Neurol.; 439(1); pp. 1-18; Oct. 2001. |
Carteron, N. L., Cytokines in rheumatoid arthritis: trials and tribulations, Mol. Med. Today, vol. 6(8), pp. 315-323, Aug. 2000. |
Cavaillon et al.; The pro-inflammatory cytokine casade; Immune Response in the Critically Ill; Springer-Verlag Berlin Hiedelberg; pp. 37-66; Jan. 21, 2002. |
Cicala et al., “Linkage between inflammation and coagulation: An update on the molecular basis of the crosstalk,” Life Sciences, vol. 62(20); pp. 1817-1824, Apr. 1998. |
Clark et al.; Enhanced recognition memory following vagus nerve stimulation in human subjects; Nat. Neurosci.; 2(1); pp. 94-98; Jan. 1999. |
Cohen, “The immunopathogenesis of sepsis,” Nature., vol. 420(6917): pp. 885-891, Dec. 2002. |
Corcoran, et al., The effects of vagus nerve stimulation on pro- and anti-inflammatory cytokines in humans: a preliminary report, NeuroImmunoModulation, vol. 12(5), pp. 307-309, Sep. 2005. |
Das, Critical advances in spticemia and septic shock, Critical Care, vol. 4, pp. 290-296, Sep. 7, 2000. |
Del Signore et al; Nicotinic acetylcholine receptor subtypes in the rat sympathetic ganglion: pharmacological characterization, subcellular distribution and effect of pre- and postganglionic nerve crush; J.Neuropathol.Exp.Neurol.; 63(2); pp. 138-150; Feb. 2004. |
Dibbs, Z., et al., Cytokines in heart failure: pathogenetic mechanisms and potential treatment, Proc. Assoc. Am. Physicians, vol. 111, No. 5, pp. 423-428, Sep.-Oct. 1999. |
Dinarello, C. A., The interleukin-1 family: 10 years of discovery, FASEB J., vol. 8, No. 15, pp. 1314-1325, Dec. 1994. |
Dorr et al.; Effect of vagus nerve stimulation on serotonergic and noradrenergic transmission; J. Pharmacol. Exp. Ther.; 318(2); pp. 890-898; Aug. 2006. |
Doshi et al., Evolving role of tissue factor and its pathway inhibitor, Crit. Care Med., vol. 30, suppl. 5, pp. S241-S250, May 2002. |
Elenkov et al.; Stress, corticotropin-releasing hormone, glucocorticoids, and the immune / inflammatory response: acute and chronic effects; Ann. N.Y. Acad. Sci.; 876; pp. 1-13; Jun. 22, 1999. |
Ellington et al., In vitro selection of RNA molecules that bind specific ligands, Nature, vol. 346, pp. 818-822, Aug. 30, 1990. |
Esmon, The protein C pathway, Crit. Care Med., vol. 28, suppl. 9, pp. S44-S48, Sep. 2000. |
Fields; New culprits in chronic pain; Scientific American; pp. 50-57; Nov. 2009. |
Fleshner, M., et al., Thermogenic and corticosterone responses to intravenous cytokines (IL-1? and TNF-?) are attenuated by subdiaphragmatic vagotomy, J. Neuroimmunol., vol. 86(2), pp. 134-141, Jun. 1998. |
Fox, D. A., Cytokine blockade as a new strategy to treat rheumatoid arthritis, Arch. Intern. Med., vol. 160, pp. 437-444, Feb. 28, 2000. |
Fox, et al., Use of muscarinic agonists in the treatment of Sjorgren' syndrome, Clin. Immunol., vol. 101, No. 3; pp. 249-263, Dec. 2001. |
Fujii et al.; Simvastatin regulates non-neuronal cholinergic activity in T lymphocytes via CD11a-mediated pathways; J. Neuroimmunol.; 179(1-2); pp. 101-107; Oct. 2006. |
Gao et al.; Investigation of specificity of auricular acupuncture points in regulation of autonomic function in anesthetized rats; Autonomic Neurosc.; 138(1-2); pp. 50-56; Feb. 29, 2008. |
Gattorno, M., et al., Tumor necrosis factor induced adhesion molecule serum concentrations in henoch-schoenlein purpura and pediatric systemic lupus erythematosus, J. Rheumatol., vol. 27, No. 9, pp. 2251-2255, Sep. 2000. |
Gaykema, R. P., et al., Subdiaphragmatic vagotomy suppresses endotoxin-induced activation of hypothalamic corticotropin-releasing hormone neurons and ACTH secretion, Endocrinology, vol. 136, No. 10, pp. 4717-4720, Oct. 1995. |
Ghelardini et al., S-(−)-ET 126: A potent and selective M1 antagonist in vitro and in vivo, Life Sciences, vol. 58, No. 12, pp. 991-1000, Feb. 1996. |
Ghia, et al., The vagus nerve: a tonic inhibitory influence associated with inflammatory bowel disease in a murine model, Gastroenterology, vol. 131, No. 4, pp. 1122-1130, Oct. 2006. |
Giebelen, et al., Stimulation of ?7 cholinergic receptors inhibits lipopolysaccharide-induced neutrophil recruitment by a tumor necrosis factor ?-independent mechanism, SHOCK, vol. 27, No. 4, pp. 443-447, Apr. 2007. |
Goyal et al., Nature of the vagal inhibitory innervation to the lower esophageal sphincter, Journal of Clinical Investigation, vol. 55, pp. 1119-1126, May 1975. |
Gracie, J. A., et al., A proinflammatory role for IL-18 in rheumatoid arthritis, J. Clin. Invest., vol. 104, No. 10, pp. 1393-1401, Nov. 1999. |
Granert et al., Suppression of macrophage activation with CNI-1493 increases survival in infant rats with systemic haemophilus influenzae infection, Infection and Immunity, vol. 68, No. 9, pp. 5329-5334, Sep. 2000. |
Green et al., Feedback technique for deep relaxation, Psycophysiology, vol. 6, No. 3, pp. 371-377, Nov. 1969. |
Gregory et al., Neutrophil-kupffer-cell interaction in host defenses to systemic infections, Immunology Today, vol. 19, No. 11, pp. 507-510, Nov. 1998. |
Groves et al.; Recordings from the rat locus coeruleus during acute vagal nerve stimulation in the anaesthetised rat; Neuroscience Letters; 379(3); pp. 174-179; May 13, 2005. |
Guslandi, M., Nicotine treatment for ulcerative colitis, Br. J. Clin. Pharmacol., vol. 48(4), pp. 481-484, Oct. 1999. |
Hansson, E.; Could chronic pain and spread of pain sensation be induced and maintained by glial activation?. Acta Physiologica, vol. 187, Issue 1-2; pp. 321R327, May/Jun. 2006. |
Harrison's Principles of Internal Medicine, 13th Ed., pp. 511-515 and 1433-1435, Mar. 1994. |
Hatton et al.; Vagal nerve stimulation: overview and implications for anesthesiologists; Int'l Anesthesia Research Society; vol. 103; no. 5; pp. 1241-1249; Nov. 2006. |
Hirano, T., Cytokine suppresive agent improves survival rate in rats with acute pancreatitis of closed duodenal loop, J. Surg. Res., vol. 81, No. 2, pp. 224-229, Feb. 1999. |
Hirao et al., The limits of specificity: an experimental analysis with RNA aptamers to MS2 coat protein variants, Mol. Divers., vol. 4, No. 2, pp. 75-89, 1999 (Accepted Jan. 13, 1999). |
Hoffer et al.; Implantable electrical and mechanical interfaces with nerve and muscle; Annals of Biomedical Engineering; vol. 8; pp. 351-360; Jul. 1980. |
Holladay et al., Neuronal nicotinic acetylcholine receptors as targets for drug discovery, Journal of Medicinal Chemistry, 40(26), pp. 4169-4194, Dec. 1997. |
Hommes, D. W. et al., Anti- and Pro-inflammatory cytokines in the pathogenesis of tissue damage in Crohn's disease, Current Opinion in Clinical Nutrition and Metabolic Care, vol. 3(3), pp. 191-195, May 2000. |
Hsu, et al., Analysis of efficiency of magnetic stimulation, IEEE Trans. Biomed. Eng., vol. 50(11), pp. 1276-1285, Nov. 2003. |
Hsu, H. Y., et al., Cytokine release of peripheral blood monoculear cells in children with chronic hepatitis B virus infection, J. Pediatr. Gastroenterol., vol. 29, No. 5, pp. 540-545, Nov. 1999. |
Hu, et al., The effect of norepinephrine on endotoxin-mediated macrophage activation, J. Neuroimmunol., vol. 31(1), pp. 35-42, Jan. 1991. |
Huston et al.; Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis; J. Exp. Med. 2006; vol. 203, No. 7; pp. 1623-1628; Jun. 19, 2006. |
Huston et al.; Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis; Crit. Care Med.; 35(12); pp. 2762-2768; Dec. 2007. |
Hutchinson et al.; Proinflammatory cytokines oppose opioid induced acute and chronic analgesia; Brain Behav Immun.; vol. 22; No. 8; pp. 1178-1189; Nov. 2008. |
Ilton et al., “Differential expression of neutrophil adhesion molecules during coronary artery surgery with cardiopulmonary bypass” Journal of Thoracic and Cardiovascular Surgery, Mosby—Year Book, inc., St. Louis, Mo, US, pp. 930-937, Nov. 1, 1999. |
Jaeger et al., The structure of HIV-1 reverse transcriptase complexed with an RNA pseudoknot inhibitor, The EMBO Journal, 17(15), pp. 4535-4542, Aug. 1998. |
Jander, S. et al., Interleukin-18 is induced in acute inflammatory demyelinating polymeuropathy, J. Neuroimmunol., vol. 114, pp. 253-258, Mar. 2001. |
Joshi et al., Potent inhibition of human immunodeficiency virus type 1 replection by template analog reverse transcriptase , J. Virol., 76(13), pp. 6545-6557, Jul. 2002. |
Kawahara et al.; SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span.; Cell. ; vol. 136; No. 1; pp. 62-74; Jan. 2009. |
Kalishevskaya et al. “The character of vagotomy-and atropin-induced hypercoagulation,” Sechenov Physiological Journal of the USSR, 65(3): pp. 398-404, Mar. 1979. |
Kalishevskaya et al.; Nervous regulation of the fluid state of the blood; Usp. Fiziol. Nauk;,vol. 13; No. 2; pp. 93-122; Apr.-Jun. 1982. |
Kanai, T. et al., Interleukin-18 and Crohn's disease, Digestion, vol. 63, suppl. 1, pp. 37-42, (year of pub. sufficiently earlier than effective US filing date and any foreign priority date) 2001. |
Katagiri, M., et al., Increased cytokine production by gastric mucosa in patients with helicobacter pylori infection, J. Clin, Gastroenterol., vol. 25, Suppl. 1, pp. S211-S214, 1997. |
Kawashima, et al., Extraneuronal cholinergic system in lymphocytes, Pharmacology & Therapeutics, vol. 86, pp. 29-48, Apr. 2000. |
Kees et al; Via beta-adrenoceptors, stimulation of extrasplenic sympathetic nerve fibers inhibits lipopolysaccharide-induced TNF secretion in perfused rat spleen; J.Neuroimmunol.; 145(1-2); pp. 77-85; Dec. 2003. |
Kensch et al., HIV-1 reverse transcriptase-pseudoknot RNA aptamer interaction has a binding affinity in the low picomolar range coupled with high specificity, J. Biol. Chem., 275(24), pp. 18271-18278, Jun. 16, 2000. |
Khatun, S., et al., “Induction of hypercoagulability condition by chronic localized cold stress in rabbits,” Thromb. and Haemost., 81(3): pp. 449-455, Mar. 1999. |
Kimball, et al., Levamisole causes differential cytokine expression by elicited mouse peritoneal macrophases, Journal of Leukocyte Biology, vo. 52, No. 3, pp. 349-356, Sep. 1992 (abstract only). |
Kimmings, A. N., et al., Systemic inflammatory response in acute cholangitis and after subsequent treatment, Eur. J. Surg., vol. 166, pp. 700-705, Sep. 2000. |
Kirchner et al.; Left vagus nerve stimulation suppresses experimentally induced pain; Neurology; vol. 55; pp. 1167-1171; Oct. 2000. |
Kokkula, R. et al., Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity, Arthritis Rheum., 48(7), pp. 2052-2058, Jul. 2003. |
Krarup et al; Conduction studies in peripheral cat nerve using implanted electrodes: I. methods and findings in controls; Muscle & Nerve; vol. 11; pp. 922-932; Sep. 1988. |
Kudrjashov, et al. “Reflex nature of the physiological anticoagulating system,” Nature, vol. 196(4855): pp. 647-649; Nov. 17, 1962. |
Kumins, N. H., et al., Partial hepatectomy reduces the endotoxin-induced peak circulating level of tumor necrosis factor in rats, SHOCK, vol. 5, No. 5, pp. 385-388, May 1996. |
Kuznik, “Role of the vascular wall in the process of hemostatis,” Usp Sovrem Biol., vol. 75(1): pp. 61-85, 1973. |
Kuznik, et al., “Blood Coagulation in stimulation of the vagus nerve in cats,” Biull. Eskp. Biol. Med., vol. 78(7): pp. 7-9, 1974. |
Kuznik, et al., “Heart as an efferent regulator of the process of blood coagulation and fibrinolysis,” Kardiologiia, vol. 13(3): pp. 10-17, 1973. |
Kuznik, et al., “Role of the heart and vessels in regulating blood coagulation and fibrinolysis,” Kagdiologiia, vol. 13(4): pp. 145-154, 1973. |
Kuznik, et al., “Secretion of blood coagulation factors into saliva under conditions of hypo-and hypercoagulation,” Voprosy Meditsinskoi Khimii, vol. 19(1): pp. 54-57; 1973. |
Kuznik, et al., “The dynamics of procoagulatible and fibrinolytic activities during electrical stimulation of peripheral nerves,” Sechenov Physiological Journal of the USSR, vol. 65; No. 3: pp. 414-420, Mar. 1979. |
Kuznik, et al., “The role of the vascular wall in the mechanism of control of blood coagulation and fibrinolysis on stimulation of the vagus nerve,” Cor Vasa, vol. 17(2): pp. 151-158, 1975. |
Lang, et al., “Neurogienic control of cerebral blood flow,” Experimental Neurology, 43(1): pp. 143-161, Apr. 1974. |
Lee, H. G., et al., Peritoneal lavage fluids stimulate NIH3T3 fibroblast proliferation and contain increased tumour necrosis factor and IL6 in experimental silica-induced rat peritonitis, Clin. Exp. Immunol., vol. 100, pp. 139-144, Apr. 1995. |
LeNovere, N. et al., Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells, J. Mol. Evol., 40, pp. 155-172, Feb. 1995. |
Leonard, S. et al., Neuronal nicotinic receptors: from structure to function, Nicotine & Tobacco Res. 3:203-223, Aug. 2001. |
Lips et al.; Coexpression and spatial association of nicotinic acetylcholine receptor subunits alpha7 and alpha10 in rat sympathetic neurons; J.Mol.Neurosci.; 30; pp. 15-16; Feb. 2006. |
Lipton, J. M. et al.; Anti-inflammatory actions of the neuroimmunomodulator ?-MSH, Immunol. Today, vol. 18, pp. 140-145, Mar. 1997. |
Loeb et al.; Cuff electrodes for chronic stimulation and recording of peripheral nerve activity; Journal of Neuroscience Methods; vol. 64; pp. 95-103; Jan. 1996. |
Madretsma, G. S., et al., Nicotine inhibits the in vitro production of interleukin 2 and tumour necrosis factor-alpha by human monocuclear cells, Immunopharmacology, vol. 35, No. 1, pp. 47-51, Oct. 1996. |
Martindale: The Extra Pharmacopoeia; 28th Ed. London; The Pharmaceutical Press; pp. 446-485; © 1982. |
Martiney et al., Prevention and treatment of experimental autoimmune encephalomyelitis by CNI-1493, a macrophage-deactivating agent, Journal of Immunology, vol. 160, No. 11, pp. 5588-5595, Jun. 1, 1998. |
McGuinness, P. H., et al., Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particulary interleukin 18) in chronic hepatitis C infection, Gut, vol. 46(2), pp. 260-269, Feb. 2000. |
Miguel-Hidalgo, J.J.; The role of glial cells in drug abuse; Current Drug Abuse Reviews; vol. 2; No. 1; pp. 76-82; Jan. 2009. |
Milligan et al.; Pathological and protective roles of glia in chronic pain; Nat Rev Neurosci.; vol. 10; No. 1; pp. 23-26; Jan. 2009. |
Minnich et al.; Anti-cytokine and anti-inflammatory therapies for the treatment of severe sepsis: progress and pitfalls; Proceedings of the Nutrition Society; vol. 63(3); pp. 437-441; Aug. 2004. |
Mishchenko, et al., “Coagulation of the blood and fibrinolysos in dogs during vagal stimulation,” Sechenov Physiological Journal of the USSR, vol. 61(1): pp. 101-107, 1975. |
Mishchenko, “The role of specific adreno-and choline-receptors of the vascular wall in the regulation of blood coagulation in the stimulation of the vagus nerve,” Biull. Eskp. Biol. Med., vol. 78(8): pp. 19-22, 1974. |
Molina et al., CNI-1493 attenuates hemodynamic and pro-inflammatory responses to LPS, Shock, vol. 10, No. 5, pp. 329-334, Nov. 1998. |
Nadol et al., “Surgery of the Ear and Temporal Bone,” Lippinkott Williams & Wilkins, 2nd Ed., 2005, (Publication date: Sep. 21, 2004), p. 580. |
Nagashima et al., Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life, J. Clin. Invest., 109, pp. 101-110, Jan. 2002. |
Nathan, C. F., Secretory products of macrophages, J. Clin. Invest., vol. 79 (2), pp. 319-326, Feb. 1987. |
Navalkar et al.; Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis; Journal of the American College of Cardiology; vol. 37; No. 2; pp. 440-444; Feb. 2001. |
Neuhaus et al.; P300 is enhanced in responders to vagus nerve stimulation for treatment of major depressive disorder; J. Affect. Disord.; 100(1-3); pp. 123-128; Jun. 2007. |
Noguchi et al., Increases in Gastric acidity in response to electroacupuncture stimulation of hindlimb of anesthetized rats, Jpn. J. Physiol., 46(1), pp. 53-58, Feb. 1996. |
Norton, Can ultrasound be used to stimulate nerve tissue, BioMedical Engineering OnLine, 2(1), pp. 6, Mar. 4, 2003. |
Palmblad et al., Dynamics of early synovial cytokine expression in rodent collagen-induced arthritis: a thereapeutic study unding a macrophage-deactivation compound, American Journal of Pathology, vol. 158, No. 2, pp. 491-500, Feb. 2, 2001. |
Pateyuk, et al.,“Treatment of Botkin's disease with heparin,” Klin. Med., vol. 51(3): pp. 113-117, Mar. 1973. |
Pavlov et al; Controlling inflammation: the cholinergic anti-inflammatory pathway; Biochem. Soc. Trans.; 34(Pt 6); pp. 1037-1040; Dec. 2006. |
Payne, J. B. et al., Nicotine effects on PGE2 and IL-1 beta release by LPS-treated human monocytes, J. Perio. Res., vol. 31, No. 2, pp. 99-104, Feb. 1996. |
Peuker; The nerve supply of the human auricle; Clin. Anat.; 15(1); pp. 35-37; Jan. 2002. |
Prystowsky, J. B. et at., Interleukin-1 mediates guinea pig gallbladder inflammation in vivo, J. Surg. Res., vol. 71, No. 2, pp. 123-126, Aug. 1997. |
Pulkki, K. J., Cytokines and cardiomyocyte death, Ann. Med., vol. 29(4), pp. 339-343, Aug. 1997. |
Pullan, R. D., et al., Transdermal nicotine for active ulceratiive colitis, N. Engl. J. Med., vol. 330, No. 12, pp. 811-815, Mar. 24, 1994. |
Pulvirenti et al; Drug dependence as a disorder of neural plasticity:focus on dopamine and glutamate; Rev Neurosci.; vol. 12; No. 2; pp. 141-158; Apr./Jun. 2001. |
Rayner, S. A. et al., Local bioactive tumour necrosis factor (TNF) in corneal allotransplantation, Clin. Exp. Immunol., vol. 122, pp. 109-116, Oct. 2000. |
Reale et al.; Treatment with an acetylcholinesterase inhibitor in alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines; J. Neuroimmunology; 148(1-2); pp. 162-171; Mar. 2004. |
Rinner et al.; Rat lymphocytes produce and secrete acetylcholine in dependence of differentiation and activation; J.Neuroimmunol.; 81(1-2); pp. 31-37; Jan. 1998. |
Robinson et al.; Studies with the Electrocardiograph on the Action of the Vagus Nerve on the Human Heart; J Exp Med; 14(3):217-234; Sep. 1911. |
Romanovsky, A. A., et al.,The vagus nerve in the thermoregulatory response to systemic inflammation, Am. J. Physiol., vol. 273, No. 1 (part 2), pp. R407-R413, Jul. 1, 1997. |
Saghizadeh et al.; The expression of TNF? by human muscle; J. Clin. Invest.; vol. 97; No. 4; pp. 1111-1116; Feb. 15, 1996. |
Saindon et al.; Effect of cervical vagotomy on sympathetic nerve responses to peripheral interleukin-1beta; Auton.Neuroscience Basic and Clinical; 87; pp. 243-248; Mar. 23, 2001. |
Saito, Involvement of muscarinic M1 receptor in the central pathway of the serotonin-induced bezold-jarisch reflex in rats, J. Autonomic Nervous System, vol. 49, pp. 61-68, Sep. 1994. |
Sandborn, W. J., et al., Transdermal nicotine for mildly to moderately active ulcerative colitis, Ann. Intern. Med, vol. 126, No. 5, pp. 364-371, Mar. 1, 1997. |
Sato, E., et al., Acetylcholine stimulates alveolar macrophages to release inflammatory cell chemotactic activity, Am. J. Physiol., vol. 274, pp. L970-L979, Jun. 1998. |
Sato, K.Z., et al., Diversity of mRNA expression for muscarinic acetylcholine receptor subtypes and neuronal nicotinic acetylcholine receptor subunits in human mononuclear leukosytes and leukemic cell lines, Neuroscience Letters, vol. 266, pp. 17-20, Apr. 30, 1999. |
Scheinman, R. I., et al., Role of transcriptional activation of I?B? in mediation of immunosuppression by glucocorticoids, Science, vol. 270, No. 5234, pp. 283-286, Oct. 13, 1995. |
Schneider et al., High-affinity ssDNA inhibitors of the review transcriptase of type 1 human immunodeficiency virus, Biochemistry, 34(29), pp. 9599-9610, Jul. 1995. |
Shafer, Genotypic testing for human immunodeficiency virus type 1 drug resistance, Clinical Microbiology Reviews, vol. 15, pp. 247-277, Apr. 2002. |
Shapiro et al.; Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery; Thromb Haemost; vol. 80(5); pp. 773-778; Nov. 1998. |
Sher, M. E., et al., The influence of cigarette smoking on cytokine levels in patients with inflammatory bowel disease, Inflamm. Bowel Dis., vol. 5, No. 2, pp. 73-78, May 1999. |
Shi et al.; Effects of efferent vagus nerve excitation on inflammatory response in heart tissue in rats with endotoxemia; vol. 15, No. 1; pp. 26-28; Jan. 2003 (Eng. Abstract). |
Snyder et al., Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors; Nature Medicine, 5(1), pp. 64-70, Jan. 1999. |
Sokratov, et al. “The role of choline and adrenegic structures in regulation of renal excretion of hemocoagulating compounds into the urine,” Sechenov Physiological Journal of the USSR, vol. 63(12): pp. 1728-1732, 1977. |
Stalcup et al., Endothelial cell functions in the hemodynamic responses to stress, Annals of the New York Academy of Sciences, vol. 401, pp. 117-131, Dec. 1982. |
Steinlein, New functions for nicotine acetylcholine receptors?, Behavioural Brain Res., vol. 95(1), pp. 31-35, Sep. 1998. |
Sternberg, E. M., Perspectives series: cytokines and the brain ‘neural-immune interactions in health and disease,’ J. Clin. Invest., vol. 100, No. 22, pp. 2641-2647, Dec. 1997. |
Stevens et al.; The anti-inflammatory effect of some immunosuppressive agents; J. Path.; 97(2); pp. 367-373; Feb. 1969. |
Strojnik et al.; Treatment of drop foot using and implantable peroneal underknee stimulator; Scand. J. Rehab. Med.; vol. 19(1); pp. 37R43; Dec. 1986. |
Sugano et al., Nicotine inhibits the production of inflammatory mediators in U937 cells through modulation of nuclear factor-kappaβ activation, Biochemical and Biophysical Research Communications, vol. 252, No. 1, pp. 25-28, Nov. 9, 1998. |
Suter et al.; Do glial cells control pain?; Neuron Glia Biol.; vol. 3; No. 3; pp. 255-268; Aug. 2007. |
Swick et al.; Locus coeruleus neuronal activity in awake monkeys: relationship to auditory P300-like potentials and spontaneous EEG. Exp. Brain Res.; 101(1); pp. 86-92; Sep. 1994. |
Sykes, et al., An investigation into the effect and mechanisms of action of nicotine in inflammatory bowel disease, Inflamm. Res., vol. 49, pp. 311-319, Jul. 2000. |
Takeuchi et al., A comparision between chinese blended medicine “Shoseiryuto” tranilast and ketotifen on the anit-allergic action in the guinea pigs, Allergy, vol. 34, No. 6, pp. 387-393, Jun. 1985 (eng. abstract). |
Tekdemir et al.; A clinico-anatomic study of the auricular branch of the vagus nerve and arnold's ear-cough reflex; Surg. Radiol. Anat.; 20(4); pp. 253-257; Mar. 1998. |
Toyabe, et al., Identification of nicotinic acetylcholine receptors on lymphocytes in the periphery as well as thymus in mice, Immunology, vol. 92(2), pp. 201-205, Oct. 1997. |
Tracey et al., Mind over immunity, Faseb Journal, vol. 15, No. 9, pp. 1575-1576, Jul. 2001. |
Tracey, K. J. et al., Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia; Nature, 330: pp. 662-664, Dec. 23, 1987. |
Tracey, K. J. et al., Physiology and immunology of the cholinergic antiinflammatory pathway; J Clin Invest.; vol. 117: No. 2; pp. 289-296; Feb. 2007. |
Tracey, K. J.; Reflex control of immunity; Nat Rev Immunol; 9(6); pp. 418-428; Jun. 2009. |
Tracey, K. J. et al., Shock and tissue injury induced by recombinant human cachectin, Science, vol. 234, pp. 470-474, Oct. 24, 1986. |
Tracey, K.J., The inflammatory reflex, Nature, vol. 420, pp. 853-859, Dec. 19-26, 2002. |
Tsutsui, H., et al., Pathophysiolocical roles of interleukin-18 in inflammatory liver diseases; Immunol. Rev., 174:192-209, Apr. 2000. |
Tuerk et al., RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase; Proc. Natl. Acad. Sci. USA, 89, pp. 6988-6992, Aug. 1992. |
Tuerk et al., Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase; Science, 249(4968), pp. 505-510, Aug. 3, 1990. |
Van Dijk, A. P., et al., Transdermal nictotine inhibits interleukin 2 synthesis by mononuclear cells derived from healthy volunteers, Eur. J. Clin. Invest, vol. 28, pp. 664-671, Aug. 1998. |
Van Der Horst et al.; Stressing the role of FoxO proteins in lifespan and disease; Nat Rev Mol Cell Biol.; vol. 8; No. 6; pp. 440-450; Jun. 2007. |
Vanhoutte, et al., Muscarinic and beta-adrenergic prejunctional modulation of adrenergic neurotransmission in the blood vessel wall, Gen Pharmac., vol. 14(1), pp. 35-37, Jan. 1983. |
vanWesterloo, et al., The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis, The Journal of Infectious Diseases, vol. 191, pp. 2138-2148, Jun. 15, 2005. |
Ventureyra, Transcutaneous vagus nerve stimulation for partial onset seizure therapy, Child's Nerv Syst, vol. 16(2), pp. 101-102, Feb. 2000. |
Vijayaraghavan, S.; Glial-neuronal interactions-implications for plasticity anddrug addictionl AAPS J.; vol. 11; No. 1; pp. 123-132; Mar. 2009. |
Villa et al., Protection against lethal polymicrobial sepsis by CNI-1493, an inhibitor of pro-inflammatory cytokine synthesis, Journal of Endotoxin Research, vol. 4, No. 3, pp. 197-204, Jun. 1997. |
Von Känel, et al., Effects of non-specific ?-adrenergic stimulation and blockade on blood coagulation in hypertension, J. Appl. Physiol., vol. 94, pp. 1455-1459, Apr. 2003. |
Von Känel, et al., Effects of sympathetic activation by adrenergic infusions on hemostasis in vivo, Eur. J. Haematol., vol. 65: pp. 357-369, Dec. 2000. |
Walland et al., Compensation of muscarinic brochial effects of talsaclidine by concomitant sympathetic activation in guinea pigs; European Journal of Pharmacology, vol. 330(2-3), pp. 213-219, Jul. 9, 1997. |
Wang et al; Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation; Nature; 421; 384-388; Jan. 23, 2003. |
Wang, H., et al., HMG-1 as a late mediator of endotoxin lethality in mice, Science, vol. 285, pp. 248-251, Jul. 9, 1999. |
Waserman, S. et al., TNF-? dysregulation in asthma: relationship to ongoing corticosteroid therapy, Can. Respir. J., vol. 7, No. 3, pp. 229-237, May-Jun. 2000. |
Watanabe, H. et al., The significance of tumor necrosis factor (TNF) levels for rejection of joint allograft, J. Reconstr. Microsurg., vol. 13, No. 3, pp. 193-197, Apr. 1997. |
Wathey, J.C. et al., Numerical reconstruction of the quantal event at nicotinic synapses; Biophys. J., vol. 27: pp. 145-164, Jul. 1979. |
Watkins, L.R. et al., Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy: evidence for vagal mediation of immune-brain communication, Neurosci. Lett., vol. 183(1-2), pp. 27-31, Jan. 1995. |
Watkins, L.R. et al., Implications of immune-to-brain communication for sickness and pain, Proc. Natl. Acad. Sci. U.S.A., vol. 96(14), pp. 7710-7713, Jul. 6, 1999. |
Webster's Dictionary, definition of “intrathecal”, online version accessed Apr. 21, 2009. |
Weiner, et al., “Inflammation and therapeutic vaccination in CNS diseases,” Nature., vol. 420(6917): pp. 879-884, Dec. 19-26, 2002. |
Westerheide et al.; Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1.; Science; Vo. 323; No. 5717; pp. 1063-1066; Feb. 2009. |
Whaley, K. et al., C2 synthesis by human monocytes is modulated by a nicotinic cholinergic receptor, Nature, vol. 293, pp. 580-582, Oct. 15, 1981. |
Woiciechowsky, C. et al., Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury, Nature Med., vol. 4, No. 7, pp. 808-813, Jul. 1998. |
Yeh, S.S. et al., Geriatric cachexia: the role of cytokines, Am. J. Clin. Nutr., vol. 70(2), pp. 183-197, Aug. 1999. |
Zamotrinsky et al.; Vagal neurostimulation in patients with coronary artery disease; Auton. Neurosci.; 88(1-2); pp. 109-116; Apr. 2001. |
Zhang et al., Tumor necrosis factor, The Cytokine Handbook, 3rd ed., Ed. Thompson, Academic Press, pp. 517-548, Jul. 1, 1998. |
Zhang et al.; Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model; Circulation Heart Fail.; 2; pp. 692-699; Nov. 2009. |
Faltys et al.; U.S. Appl. No. 15/543,391 entitled “Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator,” filed Jul. 13, 2017. |
Manta et al.; Optimization of vagus nerve stimulation parameters using the firing activity of serotonin neurons in the rat dorsal raphe; European Neuropsychopharmacology; vol. 19; pp. 250-255; Jan. 2009 (doi: 10.1016/j.euroneuro.2008.12.001). |
Pongratz et al.; The sympathetic nervous response in inflammation; Arthritis Research and Therapy; 16(504); 12 pages; retrieved from the internet (http://arthritis-research.com/content/16/6/504) ; Jan. 2014. |
Number | Date | Country | |
---|---|---|---|
20170304613 A1 | Oct 2017 | US |
Number | Date | Country | |
---|---|---|---|
61185494 | Jun 2009 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12797452 | Jun 2010 | US |
Child | 14536461 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14931711 | Nov 2015 | US |
Child | 15645996 | US | |
Parent | 14536461 | Nov 2014 | US |
Child | 14931711 | US |